Cervical cancer is one of the most common female cancers worldwide and is also the most common cancer of female genital tract in Korea. 1 Although there have been a decreased incidence and increased early detection of cervical cancer mainly due to the well-organized cytologybased screening programs especially in developed countries, 2 locally advanced cervical cancer comprises a significant proportion of the total patients with cervical cancer, particularly in developing countries. 3 Radiation therapy has been a main treatment modality for locally advanced cervical cancer.
constitutively expressed in various normal cells and is involved in the maintenance of physiologic conditions. On the other hand, COX-2 is induced during inflammation and by various mitogens, such as, growth factors and cytokines. 10 It has been proposed that COX-2 may regulate cell proliferation, mitosis, cell adhesion, apoptosis, immune surveillance and/or angiogenesis during carcinogenesis. [11] [12] [13] [14] [15] [16] Expression of COX-2 is associated with metastasis and poor prognosis in several malignancies. 8, [17] [18] [19] Furthermore several studies show that COX-2 expression may be associated with resistance to radiation and chemotherapeutic agents. 9, 20, 21 In addition, recent report indicate that COX-1 up-regulation modulates the expression of factors that may act in an autocrine/paracrine manner to enhance and sustain tumorigenesis in neoplastic cervical epithelial cells. 22 Although COX inhibitors are not used in cancer patients at present, it will be possible that non-steroidal antiinflammatory drugs (NSAIDs) may be used routinely as a simple, cheap, and safe radiosensitizer, if the evidences for the relation of COX and radiation were sufficiently accumulated. Therefore the study to clarify the relationship of COX and radioresistance of cervix cancer is an interesting and valuable subject in the field of gynecologic oncology.
Patients with cervical cancer treated by primary radiation therapy were selected from the tumor registry of Department of Therapeutic Radiology, Seoul National University Hospital from 1992 to 1997. Poor response to radiation was defined as follows; disease progression during radiation or no tumor regression after a month of radiation. Good response to radiation was that complete tumor regression during radiotherapy. For evaluation, weekly gynecologic examination was done during radiation therapy.
Among the stage IIA or higher staged uterine cervical cancer patients who had been treated with radical radiation therapy, 17 patients showed poor response to radiation. Of these patients, six patients, whose biopsy specimens were not available, were excluded, and remaining 11 patients (poor responder) were enrolled in this study. All patients in this group had histology of squamous cell carcinoma. For comparison, good response group were selected. Eleven patients (good responder) similar to poor responder in terms of stage and histology were selected.
The patients in poor response group were treated as follows; seven patients were treated with radiation therapy alone, and four patients were previously treated with neoadjuvant chemotherapy but revealed progressive disease.
In all cases, 50.4 Gy was given to the whole pelvis, but seven patients could not receive brachytherapy. Poor geometry for brachytherapy due to no tumor shrinkage was the reason. Two patients were boosted with external beam radiotherapy with cone-downed fields.
All patients in good response group were treated with radiation therapy alone. In all cases, 50.4 Gy was given to the whole pelvis, followed by one or two course of low-dose-rate brachytherapy with a total dose of 83-85 Gy to point A. If the patient had parametrial involvement, 6-10 Gy boost were given to the involved parametrium. Patient characteristics are summarized in Table 1 .
Immunohistochemical staining was performed by the ABC method using formalin-fixed, paraffin-embedded tissue sections as described previously. 23 Cervix cancer tissues were reacted with anti-COX-2 primary antibody (Transduction Lab., Lexington KY, USA) and with anti-COX-1 antibody (Santa Cruz Biotechnology, CA, USA) separately. The sensitivity of the cervix cancer cells to radiation was measured using a clonogenic assay. Cultured cells were exposed to SC-236 (10 M or 50 M) for 3 days. Then the cells were irradiated with graded doses (0, 2, 4, or 8 Gy)
of -rays using a 137 Cs source (3.7 Gy/min). Colonyforming ability of cells was assayed by re-plating them in specified numbers into 60 mm dishes in drug-free medium.
After 14 days of incubation, the cells were stained with 0.5% crystal violet in absolute ethanol, and colonies with more than 50 cells were counted. Radiation survival curves were plotted after normalizing for the cytotoxicity induced by SC-236 alone. Clonogenic survival curves were constructed from three independent experiments by fitting the average survival levels using least-squares regression by the linear-quadratic model.
COX-1 and COX-2 expressions were higher in poor responders than good responders as shown in Table 2 . The difference of COX-1 expression between two groups had marginal statistical significance (p=0.099, Fisher's exact As shown in Fig. 1, C33A Our results suggest that the expression of COX in cervical cancer might be deeply associated with the effect of radiation therapy. In the immunohistochemical staining study, patients who were resistant to radiation therapy had high COX expression. In additional experiment using clonogenic assay, COX expressing cell lines, HeLa and HT-3, were more resistant to ionizing radiation than C33A which has no COX activity. These results support the association of COX expression with radioresistance in cervix cancer.
As described in Introduction section, it has been proposed that COX-2 may play an important role in carcinogenesis, metastasis, poor prognosis, and resistance to radiation.
Recent clinical study on patients with cervical cancer who underwent radiation therapy also revealed the relationship of COX-2 expression with poor prognosis. production. 22 In addition, Narko et al. showed that COX-1 overexpression in endothelial cells implanted in mice was associated with enhanced tumorigenecity. 25 Taken together, COX-1 might be important in cell survival and/or proliferation as COX-2 did.
Numbers of studies showed that COX-2 is increased in premalignant and malignant tissues of human. These studies cover gastrointestinal tract, liver, pancreas, head and neck, lung, breast, urinary bladder, uterine cervix, endometrium, and skin. 15, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Although the exact functional role(s) of increased COX-2 in tumor tissues have not been fully elucidated yet, there have been several proposed mechanisms on the role of tumor-derived prostanoids; angiogenesis, 36 cell proliferation, 37 resistance to apoptosis, 38 and metastatic potential and/or invasiveness of a tumor. 39 On the basis of these works, lots of studies were initiated to prevent cancer and to increase an efficacy of conventional cancer therapy with the use of COX inhibitor in general population and cancer patients. Regarding radiotherapy with COX inhibitor, Liao et al. reported encouraging results in non-small cell lung cancer patients using celecoxib. 40 Currently, the Radiation Therapy Oncology Group (www.rtog. org) is conducting clinical trials in cervix cancer, lung cancer and brain tumors, using inhibitors of COX-2 in combination with chemotherapy and radiation therapy. Although cervix cancer is a radiocurable disease, there have been substantial concerns over frequent treatment failure of radiotherapy in locally advanced disease. Recent large randomized clinical trials have shown survival benefit of the concurrent use of cisplatin-based chemotherapy with radiation in patients with locally advanced disease or high-risk settings. In terms of additional chemotherapeutic agent during radiotherapy can cause more serious morbidity and increased cost, there has been incessant need for cheap and safe radiosensitizer. COX inhibitors are promising candidates for these purposes. However exact action mechanism(s) of these drugs to cancer cells is largely unknown at present and precise role(s) of COX, moreover, is only partially understood. We think that this study, although need further investigation, suggested small clue for verifying the enzymes' role in radiosensitivity modulation and for developing appropriate radiosensitizer of cervix cancer. . , ,
